11.01.10 09:19 Age: 61 days
The Institut Curie and IPSOGEN sign a scientific collaboration agreement relating to the Genomic Grade, a molecular diagnostic tool for breast cancer
Category: Breast Cancer
Paris, Marseille, January 11, 2010 - The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the current scientific knowledge on Ipsogen’s MapQuant Dx Grade Genomic, HER2 and HR tests will be increased thanks to new data established from a large population of patients treated at the Institut Curie.The aim of this collaboration is to evaluate these tests compared to current breast cancer characterization techniques. Indeed, these new tests could represent, for oncologists and pathologists, helpful decision-making tools enabling them to improve the diagnostic process and optimally adapt their therapeutic strategy to each patient.
More
